GO
Loading...

Pharmaceuticals

More

  • Juno Therapeutics soars in Nasdaq debut Friday, 19 Dec 2014 | 12:13 PM ET

    CEO Hans Bishop told CNBC investors are feeling optimistic about immunotherapy and the company's cancer treatments in development.

  • LONDON, Dec 19- European stocks held steady on Friday, pegged back by Swiss drugmaker Roche after it saw two major drugs fail tests and with Italian banks under pressure from a downgrade by S&P. "The upcoming drug pipeline was priced into the stock, but it looks unlikely these revenues will materialise," Jasper Lawler, market analyst at CMC Markets, said.

  • INDIANAPOLIS— Eli Lilly and Co. could pay more than $570 million to French pharmaceutical company Adocia under an agreement to develop a fast-acting insulin that is in the early stages of clinical testing. Lilly said Friday that it will pay $50 million upfront and an additional $280 million and $240 million if the insulin reaches some development and sales...

  • LONDON, Dec 19- European stocks edged lower on Friday, reversing an early rise, as Italian banks came under pressure from a downgrade by S&P and Swiss drugmaker Roche saw two major drugs fail tests. The FTSEurofirst 300 index of top European shares was down 0.1 percent tot 1,355.47 points at 1113 GMT, retreating after a 3 percent advance on Thursday.

  • Merck buys Swiss biotech with promising cancer drug Thursday, 18 Dec 2014 | 12:16 PM ET

    KENILWORTH, N.J.— Drugmaker Merck says it's bought a Swiss biotech company developing cancer drugs as part of its strategy to be a top player in cancer, one of the hottest pharmaceutical research areas. Merck& Co., based in Kenilworth, New Jersey, will pay up to $110 million upfront to OncoEthix. The privately held company could receive further payments of up to $265...

  • LONDON, Dec 18- Shareholders in British drugmaker GlaxoSmithKline have approved a planned deal with Switzerland's Novartis, which will see the two pharmaceutical groups trade more than $20 billion of assets. The transaction, which includes GSK buying Novartis' vaccines business, Novartis purchasing GSK's cancer drugs, and the two groups tying up in consumer...

  • Obesity can be deemed a disability at work: EU Thursday, 18 Dec 2014 | 7:00 AM ET

    Europe's top court ruled that obese people can be considered as disabled, meaning they would be covered by an EU law barring discrimination at work.

  • Amgen's leukemia drug one of world's priciest Wednesday, 17 Dec 2014 | 7:26 PM ET
    Amgen building in South San Francisco, California.

    Amgen's new leukemia drug Blincyto costs $178,000 for two courses of the treatment.

  • Supplement maker admits lying about ingredients Wednesday, 17 Dec 2014 | 5:30 PM ET

    NEWARK, N.J.— Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company. The 69- year-old Hackettstown resident faces up to five years in prison when he's sentenced March 30. Prosecutors say Steinlight admitted that the...

  • Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs. "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system,...

  • Arrests made in 2012 meningitis outbreak Wednesday, 17 Dec 2014 | 8:46 AM ET

    Federal authorities arrested 14 people related to a Massachusetts pharmacy connected to a deadly 2012 outbreak of fungal meningitis.

  • Novartis sues India's Cipla over respiratory drug Onbrez Wednesday, 17 Dec 2014 | 8:22 AM ET

    MUMBAI, Dec 17- Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price. Cipla, India's fourth-largest drugmaker by revenue, launched its copy of Onbrez in New Delhi in October, citing urgent unmet need for the...

  • Lethal injection drug bill clears Ohio Legislature Wednesday, 17 Dec 2014 | 2:08 AM ET

    COLUMBUS, Ohio— The names of companies that provide Ohio with lethal injection drugs would be shielded under a proposal the state House is poised to vote on Wednesday. Problems finding supplies of lethal drugs have created a de facto moratorium on executions in Ohio, which a decade ago was one of the country's busiest death penalty states. Ohio executed just one...

  • SINGAPORE, Dec 17- Business sentiment among Asia's top companies rose in the fourth quarter with builders switching to most optimistic from least just three months earlier due in part to increased new orders, while property developers also showed a rise in sentiment. The Thomson Reuters/ INSEAD Asian Business Sentiment Index rose to 72 in the fourth quarter, up...

  • Eli Lilly bumps up dividend for first time since 2009 Tuesday, 16 Dec 2014 | 10:44 AM ET

    INDIANAPOLIS— Shares of Eli Lilly outpaced broader trading indexes Tuesday morning, a day after the drugmaker announced its first dividend increase in more than five years. That will raise the quarterly payout to 50 cents per share, or $2 annually. Eli Lilly and Co. shares climbed about 1 percent, or 71 cents, to $70.38 Tuesday, while the Standard& Poor's 500 index...

  • Judge halts Alzheimer's drug swap until July Monday, 15 Dec 2014 | 5:27 PM ET

    District Judge Robert Sweet told Dublin- based Actavis PLC to continue making the drug Namenda available for 30 days after generic alternatives become available on July 11 "in order to allow for an orderly transition." His injunction orders the company to inform doctors and pharmacists of the decision and tells Actavis not to impose any hurdles for filling...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • ZURICH, Dec 12- Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson& Johnson's Stelara. The data follows results last year showing Cosentyx, also known as secukinumab, was superior to Amgen's Embrel in a head-to-head study. Other drugmakers working on new...

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • Ohio senators pass lethal injection drug bill Thursday, 11 Dec 2014 | 1:26 AM ET

    COLUMBUS, Ohio— Ohio is weighing changes to its lethal injection law that are meant to restart executions, but the updated law will undoubtedly lead to lawsuits that will make carrying out the next scheduled procedure on Feb. 11 impossible, a prosecutor said Thursday. The Summit County prosecutor's office is not counting on Ronald Phillips' execution happening,...